Grants and Contributions:
Title:
Preclinical Development of the Orally Bioavailable Small Molecule RSK inhibitor PMD-026 for the Treatment of Cancer
Agreement Number:
904717
Agreement Value:
$500,000.00
Agreement Date:
Apr 1, 2018 - Jul 31, 2019
Description:
Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a novel target for TNBC. PMD-026 is a first-in-class RSK inhibitor, and the proposed Project will assess pre-clinical safety of this lead compound in relevant animal models and investigate potential drug-drug interactions, in anticipation of IND submission and human trials.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6R 1E5
Reference Number:
172-2018-2019-Q1-904717
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
808104087
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 150,000 dollars.
Amendment Date
Jan 11, 2019
Recipient's Legal Name:
Phoenix Molecular Designs Ltd.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: